Physician profile
Caitlin Studley
NPI 1114440609
$5,148.67
in general payments reported to CMS, 2019-2025
31 companies · $914 in 2025
The $914 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $76.48 · 2022: $918 · 2023: $1,464 · 2024: $1,776 · 2025: $914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,154.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $970.49 | 2022-2025 | |
| Axsome Therapeutics, INC. | $505.85 | 2023-2025 | Auvelity, Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $477.52 | 2022-2025 | Caplyta |
| Novo Nordisk INC | $413.47 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $367.59 | 2022-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Vanda Pharmaceuticals INC. | $327.62 | 2022-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $257.47 | 2023-2025 | Spravato |
| Idorsia Pharmaceuticals US INC | $252.09 | 2023 | Quviviq |
| Neuronetics, INC. | $160.18 | 2024 | Neurostar Tms Therapy System |
| Teva Pharmaceuticals USA, INC. | $159.62 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lundbeck LLC | $148.86 | 2022-2024 | Rexulti |
| Jazz Pharmaceuticals INC. | $136.62 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $130.41 | 2023-2025 | Trintellix |
| Harmony Biosciences LLC | $124.98 | 2022 | |
| Pfizer INC. | $118.20 | 2023-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $111.03 | 2022-2025 | Azstarys |
| Astrazeneca Pharmaceuticals LP | $73.43 | 2024 | |
| Supernus Pharmaceuticals, INC. | $67.75 | 2023-2024 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $47.97 | 2023-2025 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $46.62 | 2024 | |
| Alkermes, INC. | $36.68 | 2024 | Aristada, Lybalvi |
| Biohaven Pharmaceutical Holding Company LTD. | $30.54 | 2022 | |
| Almatica Pharma LLC | $30.15 | 2024 | Loreev Xr |
| Tris Pharma INC | $27.97 | 2023-2024 | Dyanavel Xr |
| Lilly USA, LLC | $26.67 | 2025 | Mounjaro, Zepbound |
| Biogen, INC. | $20.05 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $18.79 | 2024 | Cobenfy |
| Collegium Pharmaceutical, INC. | $16.92 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $16.00 | 2024 | Adzenys Xr-Odt |
| Dexcom, INC. | $14.44 | 2022 | |
| Bausch Health US, LLC | $12.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlin Studley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.